Iodixanol clinical trials
Also written Visipaque and Visipaque 320.
How each study uses iodixanol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 22 Mar 1996 · VISIPAQUE 270 · NDA 020351 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2006 | 3 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 6
GE Healthcare (5) · University of Edinburgh (1) · Enrico Ammirati (1) · Duke University (1) · Bracco Diagnostics, Inc (1) · Seoul National University Bundang Hospital (1) · Deutsches Herzzentrum Muenchen (1) · Marval Pharma Ltd. (1)
Often tested with
Tested in the same studies.
Iopamidol (2) · Contrast agent BR1 (1) · Sulfur Hexafluoride (1) · Iohexol (1) · Iopromide (1) · Ioversol (1)
Studies
Open first, then newest update. How each study uses iodixanol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast MaterialCompletedPhase 4University of EdinburghNCT00558142Written as Visipaque 320How we know
- Pediatric Risk of Hypothyroidism With Iodinated Contrast MediaWithdrawnPhase 4GE HealthcareNCT03631771Written as IodixanolHow we know
- A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney DiseaseTerminatedPhase 4GE HealthcareNCT03119662Written as VisipaqueHow we know
- Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartTerminatedPhase 3GE HealthcareNCT00335335Written as iodixanolHow we know
- Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the HeartTerminatedPhase 3GE HealthcareNCT00348608Written as iodixanolHow we know
- IMaging Della PLAcca CarotideaCompletedPhase 3Enrico AmmiratiNCT03333330Written as Visipaque 320 and SonoVueHow we know
- Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy VolunteersTerminatedPhase 1Marval Pharma Ltd.NCT02063594Written as NCTX (PEGylated Liposomal Iodixanol Injection)How we know
- Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)CompletedPhase 3Duke UniversityNCT02171247Written as Visipaque 320How we know
- Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/PelvisCompletedPhase 4GE HealthcareNCT01376089Written as IodixanolHow we know
- Renal Toxicity of Iodixanol and Iopromide in Patients With Renal DysfunctionStatus unknownPhase 4Yong HuoNCT01580046Written as iodixanolHow we know
- Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSACompletedPhase 4Bracco Diagnostics, IncNCT00740207Written as VISIPAQUE 270How we know
- Contrast-medium Induced Nephrotoxicity in Patients Undergoing Coronary Angiography - Iodixanol Versus IopromideCompletedPhase 4Seoul National University Bundang HospitalNCT00823628Written as contrast agent (iodixanol)How we know
- Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)CompletedPhase 4Deutsches Herzzentrum MuenchenNCT00390585Written as Iodixanol 320How we know
Given beside what is tested · 2 — iodixanol is usual care or a partner of the new treatment
- Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CINStatus unknownNot applicableChinese PLA General HospitalNCT02718521Written as VisipaqueHow we know
- Central Venous Pressure Guided Hydration Prevention for Contrast-Induced NephropathyCompletedNot applicableChinese PLA General HospitalNCT02405377Written as VisipaqueHow we know
As the comparator · 1 — what is tested is compared with iodixanol
Codes
What other systems call iodixanol · ClinicalTrials.gg INT003200
- MeSH (NLM) C044834iodixanolConfirmed NLM, Wikidata
- UNII (FDA) HW8W27HTXXIODIXANOLConfirmed FDA, NLM, Wikidata
- RxNorm 27729Confirmed FDA, Wikidata
- Wikidata Q2419291iodixanolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65931IodixanolOne source FDA
- DrugBank DB01249One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C044834 | iodixanol | Confirmed NLM, Wikidata |
| UNII (FDA) | HW8W27HTXX | IODIXANOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 27729 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2419291 | iodixanol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65931 | Iodixanol | One source FDA |
| DrugBank | DB01249 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.